Coronary Stenosis Clinical Trial
Official title:
A Prospective, Multi-center, Randomized Study to Evaluate the Safety and Efficacy of DK ScoreTM Scoring Balloon Vesus Non-Slip Element Coronary Dilatation Catheter for Coronary Artery Stenosis
Verified date | February 2022 |
Source | DK Medical Technology (Suzhou) Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective, Multi-center, Randomized Study designed to evaluate the acute lumen gain and device procedural success of the DK ScoreTM Scoring balloon versus NSE Scoring Balloon for patients with coronary arteries stenosis.
Status | Completed |
Enrollment | 200 |
Est. completion date | December 30, 2021 |
Est. primary completion date | September 2, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Patients related 1. Age = 18 years and = 75 years. 2. Patients with symptomatic coronary artery disease with stable and unstable angina pectoralis remote myocardial infarction , asymptomatic subjects with coronary atherosclerotic stenosis causing myocardial ischemia. 3. Patients with indications for coronary artery bypass grafting. 4. Patients are able to follow protocol requirements and data collection procedures 5. Patients understand the purpose of the study, will voluntarily participate in the study and sign informed consent. Patients are willing to undergo clinical follow-up as required by this study. Lesions Related: 1. Reference vessel diameter (RVD) between 2.0 and 4.0 mm by visual estimation.. Target lesion length = 20 mm. 2. More than 70% stenosis (or more than 50% stenosis combined with symptoms of ischemia). TIMI=1. 3. One target lesion needs to be Treated. Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician. The non-target lesion need be located at another coronary artery different from the target lesion. 4. Investigator estimates that the target lesion need Cutting/Scoring balloon treatment. Target lesion is fully pre-dilated that scoring balloon is able to pass. Exclusion Criteria: Patients Related : 1. AMI within 1 week. 2. Patients has congestive heart failure or NYHA IV. 3. Renal dysfunctional (CRE>443umol/L). 4. Patient underwent heat transplant. 5. Pregnant or nursing. 6. Lifespan expectancy is less than 12 months 7. Patients with history of peptic ulcer or gastrointestinal bleeding, or the patients have a bleeding tendency evaluated by investigator. Patients are forbidden to use anticoagulation agents or anti-platelet drugs. 8. Patients are allergic to paclitaxel or heparin 9. Difficult for evaluation or treatment. 10. Patents are currently participating in another investigational drug or device study that has not yet completed its primary endpoint. 11. Patients participated in any other clinical trials less than 1 month. 12. Interventional surgery is expected to be extremely risky unsuitable for study evaluated by investigator. 13. Patient had poor compliance record and could not follow the study. Lesion Related: 1. Target Lesion located in Left Main Artery lesions and Ostial lesion within 5mm to Left Main Artery. 2. Angiography shows thrombus in Target Lesion 3. Chronic Total Occlusion Lesion |
Country | Name | City | State |
---|---|---|---|
China | Beijing Anzhen Hospital affiliated to Capital University of Medical | Beijing | Beijing |
China | Taiyuan Central Hospital | Taiyuan | Shanxi |
China | Tianjin Chest Hospita | Tianjin | Tianjin |
China | Xuzhou Third People Hospital | Xuzhou | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
DK Medical Technology (Suzhou) Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numerical Acute Lumen Gain in mm (QCA) | Acute Lumen Gain for both arms will be measure with QCA, as accessed by independent core-lab.
Angiographic endpoint will be in-lesion acute lumen gain defined as minimal lumen diameter (MLD) in lumen after dilatation by either arm device minus baseline MLD. |
During the procedure | |
Secondary | Rate of Device success in percent | Successful delivery to the target lesion, deployment, achieving less than 50% residual stenosis, and retrieval after procedure. | During the procedure | |
Secondary | Rate of Target Lesion Failure in percent | Defined as any Target Lesion Failure after procedure | 30±7 Days | |
Secondary | Rate of Patient-oriented Composite Endpoint (POCE) in percent | Patient-oriented Composite Endpoint after procedure | 30±7 Days | |
Secondary | Rate of other Complications in percent | Incidence of complications associated with the use of scoring balloon catheters | During the procedure | |
Secondary | Rate of Clinical Success in percent | Defined as <20% diameter stenosis after stenting for DCB, without in-hospital major adverse cardiac events/MI/TLR After PCI | During the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03427996 -
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
|
||
Terminated |
NCT03175523 -
HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Completed |
NCT01184183 -
Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy
|
||
Completed |
NCT00697372 -
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
|
Phase 4 | |
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03054324 -
Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis
|
||
Enrolling by invitation |
NCT06194526 -
Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography
|
||
Not yet recruiting |
NCT06039748 -
Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
|
||
Not yet recruiting |
NCT05753085 -
Multimodality Optical and Ultrasound Intravascular Imaging for Stent Optimization and Atheroma Assessment
|
N/A | |
Not yet recruiting |
NCT05471687 -
Evaluation of the Functional Impact of Coronary Stenoses in Diabetics by Spectral CT
|
N/A | |
Not yet recruiting |
NCT04569669 -
The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
|
N/A | |
Active, not recruiting |
NCT02508714 -
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents
|
N/A | |
Completed |
NCT03301246 -
Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease
|
N/A | |
Completed |
NCT03606330 -
Systemic, Pancoronary and Local Coronary Vulnerability
|
||
Completed |
NCT02870140 -
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
|
N/A | |
Not yet recruiting |
NCT06071702 -
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
|
N/A | |
Completed |
NCT02275143 -
Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis
|
N/A | |
Active, not recruiting |
NCT01794065 -
The Promus Element Rewards Study
|
N/A |